Skip to Content
Authors Jarrard DF, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze SR, Friedl A
Author Profile(s)
Journal Cancer Lett. Volume: 185 Issue: 2 Pages: 191-9
Publish Date 2002 Nov 28
PubMed ID 12169393
Abstract

We examined the status of a cell cycle checkpoint by immunohistochemically staining for p16 and pRb using multiple tissue arrays generated from 49 primary and 23 hormone-sensitive metastatic human prostate cancers. We find that p16, a cell cycle inhibitor, is paradoxically overexpressed in 83% of proliferating primary prostate cancers and increased expression correlates with a more rapid treatment failure (P=0.01) and a higher histologic grade (P=0.001). pRb staining is heterogeneous, loses expression infrequently (19%), and does not correlate with p16 expression. Loss of either p16 or pRb expression is found significantly (P=0.01) more commonly (55%) in metastatic specimens. The remarkable frequency of p16/pRb alterations and strong clinical associations implicates inactivation of this pathway as a critical determinant in prostate cancer progression.


webmaster@surgery.wisc.edu Copyright © 2017 The Board of Regents of the University of Wisconsin System